US FDA, GSK put Avandia pharmacy exit plan in place
This article was originally published in SRA
Executive Summary
As of 18 November, GlaxoSmithKline's once-top selling Type II diabetes drug Avandia (rosiglitazone) will no longer be available in US retail pharmacies. The only access to Avandia – and to its related products Avandamet (rosiglitazone and metformin) and Avandaryl (rosiglitazone and glimepiride) – will be by mail order to patients already enrolled in a tightly controlled restricted access programme, the US Food and Drug Administration and GSK said on 18 May1.